Archives
|
Entry
|
Blogger
|
Date
|
Location
|
|
Metcalfe Reflects on $2.7B 3Com Buyout, MyPunchbowl Parent Adds New Punch, $30M More for Fate Therapeutics, & More Boston Deals News
|
Ryan McBride |
11/20/09 |
Boston
|
|
ImmunoGen Nabs $1M From Amgen
|
Luke Timmerman |
11/19/09 |
Boston
|
|
Alder’s Breakout $1B Deal, Kineta Teams With UW on Vaccines, Verathon Gets Acquired, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
11/12/09 |
Seattle
|
|
Alder and New Partner, Bristol, to Give Amgen and Abbott a Run for Their Money
|
Luke Timmerman |
11/11/09 |
Seattle
|
|
Alder Scores Deal With Bristol-Myers Potentially Worth $1 Billion
|
Luke Timmerman |
11/10/09 |
Seattle
|
|
Amylin Strikes $1 Billion Deal with Takeda to Co-Develop Weight Loss Drugs
|
Luke Timmerman |
11/02/09 |
San Diego
|
|
Santaris Nabs Isis, Amgen Vets
|
Luke Timmerman |
10/28/09 |
San Diego
|
|
Five Red Flags of a Biotech, Pathway Medical Learns Lessons, Amgen Faces FDA Delay, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
10/22/09 |
Seattle
|
|
Amgen’s Dmab Faces FDA Delay
|
Luke Timmerman |
10/19/09 |
Seattle
|
|
BIL and TED’s Excellent (But Little Known) Healthcare Adventure in San Diego
|
Mary Canady |
10/19/09 |
San Diego
|
|
Faster, Cheaper Stem Cells: Fate Therapeutics Co-Founder, With Scripps Team, Finds Key
|
Luke Timmerman |
10/18/09 |
National
|
|
Dendreon Recruits Aces to Board, Amgen Seeks to Raise Hit Rate, Lee Hood Startup Gets $30M, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
10/15/09 |
Seattle
|
|
Alkermes Anti-Addiction Drug Fares Well in Clinical Trials, Amgen Takes Aim at Drug-Development Success Rate, & More Boston-Area Life Sciences News
|
Rebecca Zacks |
10/14/09 |
Boston
|
|
Lee Hood’s New Company Snags $30M to Spot Cancer and Alzheimer’s in Early Days
|
Luke Timmerman |
10/14/09 |
Seattle
|
|
Six Tips on How to Spot a Winning Biotech, From Dendreon Co-Founder Chris Henney
|
Luke Timmerman |
10/14/09 |
Seattle
|
|
Amgen’s Seattle and Boston Teams Seek to Boost Biotech Hit Rate 20 to 30 Percent
|
Luke Timmerman |
10/09/09 |
National
|
|
Bigtime Biotech Thinkers Steven Burrill and Gary Pisano Agree on Bright Future of Industry, Disagree on How to Build Value
|
Ryan McBride |
10/08/09 |
Boston
|
|
“Don’t Touch My Bags If You Please, Mr. Customs Man”
|
Stewart Lyman |
10/05/09 |
Seattle
|
|
Sequenom Shares Tank After Executives Ousted Over Data Mishandling
|
Luke Timmerman |
09/28/09 |
San Diego
|
|
Alkermes’ Ambitious Builder, Richard Pops, Grabs Reins to Re-Ignite Growth Phase
|
Luke Timmerman |
09/28/09 |
Boston
|
|
Biotech Pioneer Steve Gillis on Life as a VC, How Today’s Entrepreneurs Can Make It, and Seattle’s Future in Life Sciences (Part 2)
|
Luke Timmerman |
09/24/09 |
Seattle
|
|
Five Big Questions For Dendreon’s Analyst Day
|
Luke Timmerman |
09/24/09 |
Seattle
|
|
Biotech Pioneer Steve Gillis on Life as a VC, How Today’s Entrepreneurs Can Make It, and Seattle’s Future in Life Sciences (Part 1)
|
Luke Timmerman |
09/23/09 |
Seattle
|
|
Chase Franklin, Former Qpass Founder and CEO, Takes Charge of Daptiv
|
Gregory T. Huang |
09/21/09 |
Seattle
|
|
How Biotechs Can Stand Out in the Competition for a Big Pharma Partnership
|
Peppi Prasit |
09/17/09 |
San Diego
|
|
Amylin, Dark Horse of the Obesity Drug Battle, Follows Fast Behind Arena, Orexigen
|
Luke Timmerman |
09/14/09 |
San Diego
|
|
Acceleron, Bucking Conventional Wisdom, Pushes Ahead Drug For Bone Loss, Anemia
|
Luke Timmerman |
09/11/09 |
Boston
|
|
What Will Seattle Biotech Be Like in 20 Years? Xconomy Event Looks Far Into Region’s Future
|
Luke Timmerman |
09/10/09 |
Seattle
|
|
Orexigen Aims to Redefine Obesity, as Amgen Vet Revamps Company to Compete
|
Luke Timmerman |
09/02/09 |
San Diego
|
|
San Diego’s Palkion Chases Amgen’s Big Market, Joins Race to Develop Oral Anemia Drug
|
Luke Timmerman |
09/01/09 |
San Diego
|
|
Page 1 of
5 |
next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2009, Xconomy, Inc.
XCONOMY is a registered service mark of Xconomy, Inc.
All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
